IMPACT Medicom: Recent Episodes
IMPACT Medicom
We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic areas. If you like our podcast, please take the time to rate it and subscribe. See our website for more information, Webinars, and podcasts at: https://www.impactmedicom.com.
In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL.
Our Guest:
Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.
If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com
This episode was funded by Eli Lilly, Canada.
In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada.
Our Guests:
Dr. Versha Banerji from Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba chairs the meeting. Dr. Banerji is joined by Dr Sarit Assouline, from the Jewish General Hospital in Montreal, Quebec and Dr. Christopher Hillis, from McMaster University in Hamilton, Ontario.
If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/)
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL.
Our Guest:
Dr. Stephen Opat is the director of Clinical Haematology at Monash Health, founder and chair of the Australasian Lymphoma and Related Diseases Registry and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new targeted therapies.
Our Guest:
Dr. Barbara Melosky
Dr Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group and is creator and chair of the British Columbia Lung Cancer Biobank.
This podcast episode was sponsored by Sanofi Aventis Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the latest biomarkers that may inform treatment of upper GI cancer.
Our Guests:
Dr. Christine Brezden-Masley
Dr. Brezden-Masley is a Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health System in Toronto, Canada.
Dr. Catherine Streutker
Dr. Streutker is a Professor in the Department of Laboratory Medicine & Pathobiology at the University of Toronto.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version: https://www.youtube.com/watch?v=uk5JEUjbkDE&t=127s.
Our Guest:
Dr. S. Mark Taylor is a Facial Plastic and Reconstructive surgeon in Halifax, Nova Scotia. He is currently a Professor of Surgery at Dalhousie University. His expertise and clinical interest includes rhinoplasty/nasal surgery, eyelid surgery, management of facial paralysis, facial skin cancer, facial reconstruction, and surgery of the aging face.
Note:
The faculty for this program had full editorial control of the content.
The following program was funded by Sanofi.
Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant.
Our guest:
Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease.
Note:
The faculty for this program had full editorial control of the content.
The following program was funded by Sanofi.
Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice.
Our Guests:
Dr. Rami Kotb is a physician in the Division of Hematology, Department of Medical Oncology & Hematology at CancerCare Manitoba, Winnipeg, MB, Canada
Dr Donna Reece is the Director and a Professor of Medicine in the Program for Multiple Myeloma and Related Diseases at the University Health Network. She is also a Professor of Medicine at the University of Toronto and Princess Margaret Hospital in Toronto, ON, Canada
Note: A link to the abstract at ASH can be found here: https://ash.confex.com/ash/2023/webprogram/Paper190168.html
This podcast episode was sponsored by Sanofi-Aventis Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL.
Our Guest:
Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.
Note: The ALPINE trial is published in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.
This fifth episode of the series was recorded live from ESMO 2023 with Dr. Thomas Powles, who presented results of the EV-302 trial, and Dr. Normand Blais, Dr. Srikala Sridhar, and Dr. Bernie Eigl, who discussed the impact of new data from trials on 1L LA/mUC .
Our Guests:
Dr. Thomas Powles: Dr Thomas Powles is a Professor of Genitourinary Oncology and Director of the Barts Cancer Centre at St. Bartholomew's Hospital. He is also the Lead for Solid Tumour Research in London, England.
Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.
Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers.
Dr. Bernie Eigl: Dr. Eigl is a medical oncologist specializing in genitourinary oncology, with a special research interest in bladder and prostate cancers at BC Cancer. He ia alo a Clinical Associate Professor at the University of British Columbia.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.
This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.
In this first episode taken from the webinar, Dr. Normand Blais introduces the speakers and discusses the unmet needs of patients with locally advanced metastatic urothelial carcinoma in Canada.
Our Guests:
Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.
Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.
Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers.
The full webinar can be found on our website at: https://www.impactmedicom.com/video-capsules.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.
This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.
In this third episode taken from the webinar, Dr. Srikala Sridhar presents a clinical case on the treatment of locally advanced metastatic urothelial carcinoma, highlighting the role of enfortumab vedotin plus pembrolizumab in the treatment plan.
Our Guests:
Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.
Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.
Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.
This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.
In this fourth and final episode taken from the webinar, Drs Normand Blais, Terence Friedlander, and Srikala Sridhar provide their perspective on the management of the first-line treatment locally advanced metastatic urothelial carcinoma, including a discussion of the optimal use of enfortumab vedotin plus pembrolizumab and management of associated adverse events.
Our Guests:
Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.
Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.
Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.
This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.
In this second episode taken from the webinar, Dr. Terrence Friedlander presents clinical data in the first-line setting and provides a US perspective on how he manages the treatment of locally advanced metastatic urothelial carcinoma.
Our Guests:
Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.
Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.
Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
Welcome to our podcast episode on external quality assurance (or eQA) for testing biomarkers in oncology, hosted by Anna Christofides. In this episode, we discuss with Dr. Emina Torlakovic, the use of eQA to aid in the improvement of biomarker testing in Canada .
Our Guest:
Dr. Emina Torlakovic is a Professor in Department of Laboratory Medicine and Pathobiology at the University of Toronto. She is also a Staff Hematopathologist and Director of Biomarker Development and Quality Assurance at the University Health Network. Dr. Torlakovic is also a founding member of NordiQC, Canadian Immunohistochemistry Quality Control (CIQC), as well as the International Society for Immunohistochemistry and Molecular Morphology. She is Chair of the Canadian Association of Pathologists’ National Standards Committee for High Complexity Testing and also co-directs CIQC.
This podcast episode was sponsored by Merck, Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this third episode, we discuss the management of peripheral neuroptathy associated with enfortumab vedotin, or EV.
Our Guests:
This third episode on the management of neuropathy is hosted by Dr Srikala Sridhar, Professor in the Department of Medicine at the University of Toronto and a Genitourinary Medical Oncologist at the Princess Margaret Cancer.
In this episode, Dr Sridhar interviews Dr Warren Mason, a Professor in the department of medicine at the University of Toronto and a neuro-oncologist at the Princess Margaret Cancer Center.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this second episode, we discuss the management of skin reactions associated with enfortumab vedotin, or EV.
Our Guests:
In this episode, Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC interviews dermatology specialist, Dr. Joel Claveau.
Dr. Joel Claveau is a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this first episode, we discuss the evolution of therapy from chemotherapy to treatment with novel therapies such as enfortumab vedotin, or EV. We then focus on the key clinical trials examining the efficacy and safety of EV for the treatment of urothelial carcinoma.
Our Guests:
We introduce the topic in our first episode with Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC.
Dr. Joel Claveau, a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the latest updates in the treatment of CLL with Dr. Laurie Sehn, Dr. Matthew Davies, and Dr. Constantine Tam.
Our Guests:
Dr. Sehn
Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia.
Dr. Davids
Dr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School.
Dr. Tam
Dr. Constantine Tam is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.
In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impact of the results of the ALPINE trial for clinical practice given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory CLL and SLL.
Our Guest:
Dr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to our 13th podcast episode in the Precision Medicine Series. In this episode, hosted by Anna Christofides, we discuss diagnostic, prognostic and predictive biomarkers for the treatment of endometrial cancer.
Our Guests:
- Dr. Jessica McAlpine, a Gynaecologic Oncologist and Division Head in the Division of Gynaecologic Oncology at the University of British Columbia
- Dr. Mary Kinloch, a Gynaecologic Pathologist and Division Head of Pathology and Laboratory Medicine at the University of Saskatchewan
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Live From ASH, New Orleans:
In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans.
Our Guest:Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. In this episode, Dr. Sehn discusses the impact of the results of the ALPINE trial for clinical practice in Canada given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Live From ASH, New Orleans:
In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA.
Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.
Our Guest:
Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode we discuss current and emerging systemic treatments for advanced, unresectable biliary tract cancers, as well as the barriers to accessing new treatments in Canada.
Our Guest:
Dr. Howard Lim is a Medical Oncologist, specializing in the treatment of gastrointestinal cancers at the BC Cancer Agency in Vancouver and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia.
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to our 12th episode in the precision medicine in oncology podcast series. In this episode we discuss diagnostic, prognostic and predictive biomarkers for the treatment of breast cancer.
Our Guest:
Our guest for this episode is Dr. David Cescon, a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Ontario, where his clinical practice is devoted to the care of patients with breast cancer.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination.
Our Guest:
Our guest is Dr. Cowan, who is an Associate Scientist at The Ottawa Hospital Research Institute and Assistant Professor at The University of Ottawa. Dr. Cowan is also cross-appointed as an Assistant Professor at the Department of Biochemistry, Microbiology and Immunology and a Physician for the Division of Infectious Diseases at The Ottawa Hospital in Ontario. Her clinical and research focus is on prevention of infection in immunocompromised patients
Sponsored by AstraZeneca Canada
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination.
Our Guest:
Our guest is Dr. Dimas Yusuf, Medical Oncologist and specialist in general internal medicine at Pacific Specialty Care in Delta, BC. He is also the Managing Director of OncoCare Health Incorporated in Vancouver, BC, which delivers cutting edge technologies and insights to advance cancer care.
Sponsored by AstraZeneca Canada
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this second episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with hematological malignancies who are not able to mount a sufficient antibody response to vaccination.
Our Guest:
Our guest is Dr Laurie Sehn, Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia.
Sponsored by AstraZeneca Canada
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Bienvenue dans la série de balados d’IMPACT Medicom sur la prophylaxie contre la COVID-19.
Notre invitée
Notre invitée dans l’épisode d’aujourd’hui est Annick Dufour, chef adjointe au département de pharmacie du CISSS Montérégie-Centre, au Québec au niveau des soins pharmaceutiques, de la recherche clinique et de l’oncologique. Elle est pharmacienne en oncologie depuis plusieurs années. Elle est également présidente du Comité d’évolution de la pratique des soins pharmaceutiques (CEPSP) du programme québécois de cancérologie du ministère de la Santé et des Services sociaux (MSSS)
Sponsored by AstraZeneca Canada
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to our podcast episode on the treatment of urothelial carcinoma. In this episode, hosted by Anna Christofides, we discuss updated results of the Phase 3 EV-301 trial, presented at ASCO 2022, that examined the efficacy and safety of Enfortumab Vedotin, or EV, versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
Our Guest:
Our guest for this episode is Dr Nimira Alimohamed, Medical Oncologist and Clinical Associate Professor of Medicine at the University of Calgary and Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode, we discuss immunotherapy treatment and biomarker testing for metastatic cervical cancer.
Our Guest:
Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynecology at Dalhousie University, Halifax, Canada. Dr. Bentley is Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC) and the Society of Canadian Colposcopists (SCC). He is also Past-President of the Society of Gynecologic Oncology of Canada (GOC). He serves on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode of IMPACT Medicom’s podcast series on immunotherapies in Head and Neck Squamous Cell Carcinoma, we discuss the medical oncologist’s role in managing patients with HNSCC, and how immunotherapies fit in to their practice.
Our Guest:
Dr. Martin Smoragiewicz is a Medical Oncologist at the Odette Cancer Centre, part of Sunnybrook Health Sciences Centre in Toronto, Ontario. His clinical expertise is in Genitourinary and Head & Neck cancers and his research focuses on improving therapeutics, with a special interest in immunotherapy. Dr. Smoragiewicz is the principal investigator on numerous clinical trials, and the lead for Head & Neck clinical trials at the Odette Cancer Centre.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to episode 11 of our Precision Medicine in Oncology series. In this episode, we discuss the development of a pan-Canadian consensus paper on the selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer.
Our Guest:
Our guest for this episode is Dr. Anna Tinker, Medical Oncologist at BC Cancer in Vancouver, Canada. Dr. Tinker is also a Clinical Associate Professor in the Department of Medicine at the University of British Columbia.
This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to the second episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas (HNSCC). This episode includes a discussion of:
- The role of the surgical oncologist in managing patients with HNSCC
- How immunotherapy fits into to the surgical oncologist's practice
Our Guest:
Our guest is Dr. Antoine Eskander, a head and neck surgical oncologist at Sunnybrook Health Sciences Centre and Assistant professor in the department of otolaryngology at the University of Toronto. He is also an adjunct scientist at the Institute for Clinical Evaluative Sciences.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to the first episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas. This episode includes a discussion of:
- The role of the pathologist in the management of head and neck cancers
- PD-L1 testing as a predictive biomarker for immunotherapy in HNSCC
- Improving the testing process for PD-L1
Our Guest:
Our guest is Dr. Matthew Cecchini, Pathologist in the Department of Pathology and Laboratory Medicine at London Health Sciences Centre and Assistant Professor at Western University in London Ontario Canada. Dr. Cecchini specializes in pulmonary, head and neck, and molecular pathology. His research interests include the application of digital and machine learning tools in pathology.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode, we discuss the treatment of triple negative breast cancer (TNBC) with Dr. Stephen Chia. We cover:
- The use of immunotherapies to treat TNBC
- Biomarkers that can determine which patients will best respond to immunotherapies
- The challenges of testing for PDL-1
Our Guest:
Dr. Stephen Chia is a professor in the division of medical oncology and staff medical oncologist with BC Cancer, in Vancouver. He has held many leadership roles at BC Cancer, including Head of the Division of Medical Oncology UBC, Head of the Department of Clinical Research, BC Cancer, and Chair of the BC Cancer Breast Tumour Group. He has also been the Co-Chair of the Breast Disease Site for Canadian Cancer Trials Group (CCTG).
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Bienvenue à la série de fichiers balados d’IMPACT Medicom sur la vaccination contre la COVID-19. Roula Drossis est l’animatrice de l’épisode d’aujourd’hui.
Dans cet épisode, nous discutons de l'immunisation contre la COVID-19 et de la façon dont nous pouvons protéger nos populations les plus vulnérables qui ne sont pas en mesure de produire une réponse anticorps suffisante à la vaccination.
Notre invité:
Notre invité à l’épisode d’aujourd’hui est le Dr Alex Carignan. Le Dr Carignan est médecin microbiologiste-infectiologue au Centre hospitalier universitaire de Sherbrooke. Il est également professeur titulaire et chercheur au département de microbiologie et d’infectiologie de l’Université de Sherbrooke.
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination.
In this fourth episode of the series, we discuss:
- Response to COVID-19 vaccines in the general population
- Response to COVID-19 vaccines in immunocompromised people
- The impact of COVID-19 on patients with hematologic malignancies
- The potential role of pre- and post- COVID-19 exposure prophylaxis for people with hematologic malignancies
Our Guest:
Our guest on today’s episode is Dr. Carolyn Owen, who is an an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary.
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination.
In this third episode of the series, we discuss:
- Response to COVID-19 vaccines in the general population
- Response to COVID-19 vaccines in immunocompromised people
- The evolution of the pharmacist's role in immunization
- The potential role of pre- and post- COVID-19 exposure prophylaxis for people who are immunocompromised
Our Guest:
Our guest is Ajit Johal, who is a clinical instructor for the University of British Columbia Faculty of Pharmaceutical Sciences Program. Ajit has been providing immunizations and clinical education since 2012. In 2018, he started an organization called immunize.io, with a mission statement of "taking our best shot at immunizing the world". Through "immunize.io" he has worked with numerous organizations and communities to address “vaccine hesitancy” and improve access to vaccinations.
Ajit also has his own podcast, which is available at: https://open.spotify.com/show/4BEzRqoLWLoQR5yM0pnW8I?si=Mc-5cOAjQNSjctNwTqtKmA&utm_source=copy-link
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination.
In this first episode of the series, we discuss:
- Response to COVID-19 vaccines in the general population
- Populations who have a reduced response to vaccination
- The difference between active and passive immunization
- The potential role of pre- and post- COVID-19 exposure prophylaxis for vulnerable populations
Our Guest:
Our guest is Dr. Brian Conway, who is an infectious diseases specialist and the medical director of the Vancouver Infectious Diseases Centre, dedicated to the development and evaluation of systems of care for inner city vulnerable population. The models his team has established have led to increased access to HIV and HCV care as well as addiction services in a unique and durable manner. He is an adjunct professor in the Faculty of Health Sciences at Simon Fraser University. In 2012, he received the Queen Elizabeth II Diamond Jubilee Medal for long-standing service to the country in the field of HIV. In 2020, the Coalition for Global Hepatitis Elimination recognized Dr. Conway’s group as one of 6 global elimination champions. In the times of COVID-19, he has been sought out by local and national media to help Canadians make sense of the pandemic. Through generous funding from the Public Health Agency of Canada, he is currently involved in optimizing vaccine and treatment understanding and uptake among inner city residents.
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this podcast series on pre- and post- COVID-19 prophylaxis, we discuss immunization against COVID-19 and how we can protect our most vulnerable populations who are not able to mount a sufficient antibody response to vaccination.
In this second episode of the series, we discuss:
- Response to COVID-19 vaccines in the general population
- Response to COVID-19 vaccines in people who have received a solid organ transplantation
- The potential role of pre- and post- COVID-19 exposure prophylaxis for people with solid organ transplants
Our Guest:
Our guest is Dr. Zain Chagla, who is an associate professor at McMaster University, co-medical director of infection control at St. Joseph’s Healthcare Hamilton and a consultant in infection control at Woodstock General Hospital. Dr. Chagla’s research and clinical interests include monoclonal antibody use in COVID-19, infections in renal transplantation, global health and tropical medicine, education and antimicrobial stewardship, and ultrasound in infectious diseases.
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode of IMPACT Medicom’s Precision Medicine in Oncology podcast series, we discuss the evolving biomarker landscape in gastrointestinal malignancies and some of the advantages and challenges of implementing and accessing biomarker testing.
Our guest:
Dr. Rosalyn Juergens is a medical oncologist with clinical expertise in lung and esophageal cancer. She was on the faculty at The Johns Hopkins Medical Institute from 2007-2010 until she joined the faculty at McMaster University in 2011. Dr. Juergens’ leadership roles include serving as chair of the Lung Disease Site Team and Head of the Department of Clinical Trials at the Juravinski Cancer Centre in Hamilton, Ontario. She is also the chair of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee and Medical Advisory Committee Chair for Lung Cancer Canada. Dr. Juergens’ research interests involve improving therapeutics and diagnostics in cancer, with a focus on developmental therapeutics and Phase I and II clinical trials.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to episode 9 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the second episode in a 3-part series on ovarian cancer. This episode, hosted by IMPACT Medicom’s Sarah Doucette, features a debate on whether first-line maintenance therapy with PARP inhibitors can be considered a curative strategy in patients with advanced, BRCA-mutated epithelial ovarian cancer.
Our Guests:
Dr. Taymaa May
Taymaa May is a surgical scientist at the University Health Network and an Associate Professor at the University of Toronto. Dr. May is the surgical oncology lead for Toronto central south, Ontario Health/Cancer Care Ontario and the chair of the Gynecologic Oncology Group of Ontario. She is the director of clinical specialty programs in the department of surgical oncology and a member of the Princess Margaret executive. She is also the current chair of the Gynecologic Oncology of Canada’s (GOC) Annual General Meeting and is a member of GOC’s board of directors. Dr. May’s research focuses on surgical innovation and translational research in ovarian cancer.
Dr. James BentleyDr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynaecology at Dalhousie University. He is a Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC), the Society of Gynaecologic Oncology of Canada (GOC), and the Society of Canadian Colposcopists, and is the past Chair of the Royal College Nucleus Committee for Gynecologic Oncology. He continues to serve on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer. Dr. Bentley's clinical interests lie in the field of cervical cancer prevention, colposcopy, clinical trials including the application of HPV Vaccines and chemotherapy trials.
Links:
SOLO-1 5-year update: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltext
Correlation between BRCA status and surgical cytoreduction: https://www.gynecologiconcology-online.net/article/S0090-8258(21)00540-0/fulltext
This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to episode 8 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the first in a series of episodes focusing on ovarian cancer. In this episode, we discuss the importance of BRCA testing for patients with advanced epithelial ovarian cancer and how national initiatives have helped to improve BRCA testing standards across the country.
Our Guests:
Dr. Janice Kwon, Gynecologic Oncologist at Vancouver Coastal Health and Vice Head and Professor in the Department of Obstetrics and Gynecology at the University of British Columbia. Dr. Kwon serves as Chair of both the Priority and Evaluations Committee at BC Cancer and the National BRCA Collaborative. Her expertise is in hereditary cancer syndromes and conducting cost-effectiveness analyses of testing criteria and risk-reducing
interventions.
Dr. Alon Altman, Gynecologic Oncologist and Professor at the University of Manitoba, and the Winnipeg Health Sciences Centre/Cancercare Manitoba. Dr. Altman is the president elect for the Society of Gynecologic Oncology of Canada (the GOC). He is actively involved in multiple other university, national and international committees including serving as program director for the department of Obstetrics and Gynecology, chair of the University Medical Group (UMG), vice chair for the Medical Management Safety Committee (MMSC) at CancerCare Manitoba, and Gynecologic oncology track lead for the FIGO 2021 Scientific planning committee.
This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this seventh episode of our podcast series on precision medicine, hosted by Anna Christofides, we discuss genomic testing in prostate cancer. Our episode focuses on the evolution and uptake of genetic testing in prostate cancer. We discuss testing for homologous recombination repair (HRR) genes and their association with prognosis and influence on treatment decisions. We also discuss somatic vs germline testing and who is responsible for ordering genomic tests.
Our guest:
Our guest on today’s episode is Dr. Neil Fleshner, who is the Martin Barkin Chair and a Professor of Surgery at the Division of Urology at the University of Toronto in Toronto, Ontario. He is also affiliated with Sunnybrook Hospital, Mount Sinai Hospital, Princess Margaret Cancer Centre (UHN), and the Toronto General Hospital (UHN).
This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to episode 6 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology. In this episode Dr. Gonzalez discusses testing methodology, particularly for mismatch repair deficiency, as well as potential emerging biomarkers for metastatic colorectal cancer.
Our Guest:
Dr. Raul Gonzalez is an Associate Professor of Pathology at Harvard Medical School and the Director of Gastrointestinal Pathology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Gonzalez is a surgical pathologist specializing in gastrointestinal pathology. He is the Editor- in-Chief of Pathology Outlines and the Reviews Editor for Histopathology. He also serves as the Vice Chair for the College of American Pathologists Surgical Pathology Committee and the Website Committee Chair for the Hans Popper Hepatopathology Society.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom’s Macroglobulinemia. Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients.
Our Guests
Our first guest, Dr. Constantine Tam, is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is also the lead author on the ASPEN trial, and provides a detailed look at the key data from this study.
We are then joined by Dr. Carolyn Owen, an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. Dr. Owen discusses the potential impact of the data from the ASPEN trial on Canadian clinical practice. And how zanubrutinib may fit into the Canadian treatment algorithm for Waldenstrom’s Macroglobulinemia.
This podcast episode was sponsored by Beigene Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:
· The current standards for molecular testing in metastatic colorectal cancer
· The potential benefit of a Canadian guideline for molecular testing in metastatic colorectal cancer
Our guest:
Dr. Sharlene Gill is Professor of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver. Dr. Gill earned her MD from the University of British Columbia and completed a fellowship in gastrointestinal oncology at the Mayo Clinic (Rochester, MN). She also received a Master of Public Health degree from the Harvard School of Public Health and completed her MBA at the Kenan-Flagler School of Business at the University of North Carolina. Dr. Gill currently specializes in the treatment of gastrointestinal malignancies and serves as the Chair of the Canadian Clinical Trials Group GI Disease Site Committee. In addition, she is President-Elect of the Canadian Association of Medical Oncologists and is Editor-in-Chief for the peer-reviewed journal Current Oncology.
This podcast episode was sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Background
- Lung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics)
- Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Canadian Cancer Statistics)
- Two clinical trials, the Dutch-Belgian screening trial (NELSON) and the United States National Lung Screening Trial (NLST), have demonstrated the value of lung cancer screening in reducing mortality rates in high-risk populations.
- The lung cancer community across Canada is therefore united in the belief that screening programs should be implemented nationwide.
- Lung Cancer Screening programs have been announced across Canada. The Ontario program launched in April 2021 and the program in Quebec launched in June 2021. A program in BC was announced in 2020 and will launch in the near future. Other provinces across Canada are working on developing screening programs also.
- In this podcast series, we discuss the importance of lung cancer screening and aim to raise awareness of these programs in Canada in order to improve patient care.
Our Guests
Dr. Donna Maziak: Thoracic surgeon and surgical oncologist at the Ottawa Hospital, Ottawa, Ontario.
Chantal Bornais: Nurse navigator at the Ottawa Hospital, Ottawa, Ontario.
Resources
Lakeridge Health in Oshawa: https://www.lakeridgehealth.on.ca/en/central-east-regional-cancer-program/lung-cancer-screening-pilot.asp
- The Ottawa Hospital: https://www.ottawahospital.on.ca/en/clinical-services/deptpgrmcs/programs/cancer-program/what-we-offer-our-programs-and-services/lung-screening/
- Health Sciences North in Sudbury: https://www.hsnsudbury.ca/portalen/rcp/hrlcsp
- Princess Margaret Hospital in Toronto: https://www.trcp.ca/en/screening/screening-programs/Pages/lung.aspx
- Cancer Care Ontario: https://www.cancercareontario.ca/en
TO FIND A SCREENING PROGRAM NEAR YOU: https://right2survive.ca/resource-centre/screening/
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
Background
- Lung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics)
- Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Canadian Cancer Statistics)
- Two clinical trials, the Dutch-Belgian screening trial (NELSON) and the United States National Lung Screening Trial (NLST), have demonstrated the value of lung cancer screening in reducing mortality rates in high-risk populations.
- The lung cancer community across Canada is therefore united in the belief that screening programs should be implemented nationwide.
- Lung Cancer Screening programs have been announced across Canada. The Ontario program launched in April 2021 and the program in Quebec launched in June 2021. A program in BC was announced in 2020 and will launch in the near future. Other provinces across Canada are working on developing screening programs also.
- In this podcast series, we discuss the importance of lung cancer screening and aim to raise awareness of these programs in Canada in order to improve patient care.
Our Guests
Dr. Stephen Lam:Professor of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer. Dr. Lam is a Distinguished Scientist, and Leon Judah Blackmore Chair in Lung Cancer Research at the BC Cancer Research Center. He was the recipient of the Friesen-Rygiel Award for Outstanding Canadian Academic Discovery and the Gustav Killian Medal by the World Association of Bronchology for his pioneering contributions to the field of early lung cancer diagnosis, the Distinguished Achievement Award from the University of British Columbia and the Joseph Cullen Award for life-time scientific achievements in lung cancer prevention research by the International Association for the Study of Lung Cancer.
Dr. Rakesh Patel: General practitioner from Silverado Medical Clinic in Calgary, Alberta.
ResourcesBC Press release http://www.bccancer.bc.ca/about/news-stories/news/2020/b-c-launches-lung-cancer-screening-program-%E2%80%93-the-first-in-canada
CPAC Report: https://s22457.pcdn.co/wp-content/uploads/2021/01/lung-cancer-screening-environmental-scan-2019-2020-Jan132021-EN.pdf
TO FIND A SCREENING PROGRAM NEAR YOU: https://right2survive.ca/resource-centre/screening/
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
Renseignements généraux
- Le cancer du poumon est l’une des formes de cancer les plus courantes ainsi que la principale cause de décès par cancer au Canada. (Statistiques canadiennes sur le cancer, 2020).
- Le taux de survie des patients atteints d’un cancer du poumon est faible. La survie nette à trois ans est de 71 % pour les cas diagnostiqués au stade 1, et chute à 5 % pour les cas diagnostiqués au stade 4. Au Canada, environ la moitié des cancers du poumon ont atteint le stade 4 au moment du diagnostic. (Statistiques canadiennes sur le cancer, 2020).
- Deux études cliniques, soit l’étude néerlando-belge sur le dépistage NELSON et une étude américaine nationale sur le dépistage du cancer du poumon (l’étude NLST), ont montré l’utilité du dépistage du cancer du poumon dans la réduction du taux de mortalité chez les populations à haut risque.
- Au Canada, il y a consensus au sein de la communauté du cancer du poumon quant à la nécessité de mettre en œuvre des programmes de dépistage à l’échelle nationale.
- On a annoncé la mise en œuvre de programmes de dépistage du cancer du poumon à l’échelle du Canada. L’Ontario et le Québec ont lancé les leurs en avril et en juin 2021, respectivement. La Colombie-Britannique a fait l’annonce de son programme en 2020; celui-ci sera lancé sous peu. D’autres provinces travaillent également à l’élaboration de programmes de dépistage.
- Dans cette série de balados, nous discuterons de l’importance du dépistage du cancer du poumon et des moyens de faire connaître ces programmes au Canada afin d’améliorer les soins offerts aux patients.
Invités
Dre Nicole Bouchard: Pneumologue au département de médecine de l’Université de Sherbrooke, Québec.
Dr Richard Dumouchel: Omnipraticien à la Clinique médicale du Coteau, à Saint-Jean-sur-Richelieu, Québec.
Résources
https://right2survive.ca/resource-centre/screening/
https://www.quebec.ca/en/health/advice-and-prevention/screening-and-carrier-testing-offer/lung-cancer-screening-demonstration-project
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
Background
- Lung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics)
- Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Canadian Cancer Statistics)
- Two clinical trials, the Dutch-Belgian screening trial (NELSON) and the United States National Lung Screening Trial (NLST), have demonstrated the value of lung cancer screening in reducing mortality rates in high-risk populations.
- The lung cancer community across Canada is therefore united in the belief that screening programs should be implemented nationwide.
- Lung Cancer Screening programs have been announced across Canada. The Ontario program launched in April 2021 and the program in Quebec launched in June 2021. A program in BC was announced in 2020 and will launch in the near future. Other provinces across Canada are working on developing screening programs also.
- In this podcast series, we discuss the importance of lung cancer screening and aim to raise awareness of these programs in Canada in order to improve patient care.
Our Guests
Dr. Paul Wheatley-Price:Associate Professor in the Department of Medicine at the University of Ottawa and Medical Oncologist at The Ottawa Hospital Cancer Centre, specializing in the treatment of thoracic malignancies and carcinoma of unknown primary. Since 2016, Dr. Wheatley-Price has previously served as President of Lung Cancer Canada.
Dr. Jeffery Habert: General practitioner in Thornhill, ON and Assistant Professor in the Department of Family and Community Medicine at the University of Toronto.
ResourcesONTARIO
- Lakeridge Health in Oshawa: https://www.lakeridgehealth.on.ca/en/central-east-regional-cancer-program/lung-cancer-screening-pilot.asp
- The Ottawa Hospital: https://www.ottawahospital.on.ca/en/clinical-services/deptpgrmcs/programs/cancer-program/what-we-offer-our-programs-and-services/lung-screening/
- Health Sciences North in Sudbury: https://www.hsnsudbury.ca/portalen/rcp/hrlcsp
- Princess Margaret Hospital in Toronto: https://www.trcp.ca/en/screening/screening-programs/Pages/lung.aspx
BRITISH COLUMBIA
- The BC Lung Screen Trial: http://www.bccancer.bc.ca/our-research/participate/lung-health
CPAC Report: https://s22457.pcdn.co/wp-content/uploads/2021/01/lung-cancer-screening-environmental-scan-2019-2020-Jan132021-EN.pdf
TO FIND A SCREENING PROGRAM NEAR YOU: https://right2survive.ca/resource-centre/screening/
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:
· The initiatives developed by Colorectal Cancer Canada to help progress access to genomic profiling and precision medicine for all cancer patients
· The patient’s perspective on education, access, and value of genomic profiling
· Access to genomic profiling in Quebec
· The value of IMPACT Medicom’s comprehensive genomic profiling prioritization report: https://www.impactmedicom.com/publications/reports
Our guest:
Barry D. Stein is the President and CEO of Colorectal Cancer Canada and is himself a survivor of metastatic colorectal cancer. He is an established lawyer in the fields of commercial and corporate law with GWBR, LLP in Montreal, where he dedicates a significant portion of his practice to labour law, as well as litigation in health and administrative law. Barry is the past president of the Coalition Priorité Cancer au Québec. He is also past chair of the IQVIA Advisory Council for the Advancement of Health in Quebec and a member of the Board of Directors of the Canadian Personalized Healthcare Innovation Network, EXACTIS Innovation, and the Quebec Clinical Research Organization in Cancer (Q-CROC).
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
In this episode of our podcast, we are joined by a very special guest, Dr. John Kuruvilla, who is an Associate Professor of Medicine at the University of Toronto and a Clinical Investigator in the Division of Medical Oncology and Hematology at Princess Margaret Hospital in Toronto.
We discuss:
- The current treatment of classical Hodgkin’s Lymphoma
- The use of checkpoint inhibitors for these patients
- Results of the KEYNOTE-204 trial, a randomized phase III trial of pembrolizumab versus brentuximab vedotin in relapsed or refractory Hodgkin’s Lymphoma
- How future research will address some key questions in this area
This podcast episode is sponsored by Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
Welcome to IMPACT Medicom’s MYTHBUSTER series, addressing COVID-19 vaccine hesitancy. This series is aimed at health care professionals who are on the front lines of vaccine delivery, to help address common sources of misinformation around COVID-19 vaccines.
In the third episode of the series, hosted by Anna Christofides (owner of IMPACT Medicom), we discuss with Dr. Raywat Deonandan:
- Strategies and tactics for discussing myths around COVID-19 with the public
- The difference between individual and population risk and how to discuss these concepts
- Lessons we can learn from other countries and experiences
- The efficacy of COVID-19 vaccines against known variants
Our guestDr. Ray Deonandan is an Epidemiologist and Associate Professor at the University of Ottawa, specializing in global health. Dr. Deonandan is a well-known science communicator, appearing on numerous news outlets throughout the COVID-19 pandemic in his effort to educate the public on the latest data.
This podcast episode is sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
Podcast details:
In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:
· The evolving role of genomics in a pathologist’s tool kit for informing care in oncology
· The value of comprehensive genomic profiling (CGP) compared to single-gene tests
· The barriers to accessing CGP in Ontario
· What factors institutions should consider when deciding how to implement CGP
Our guest:
Dr. Brandon Sheffield is an anatomical pathologist at William Osler Health System in Brampton, Ontario, where he serves as Medical Director of Immunohistochemistry and Molecular Pathology, and Physician Lead of Research. He received his Doctor of Medicine at the University of Toronto and completed his anatomical pathology residency at the University of British Columbia. Given his interest in molecular genetic pathology, Dr. Sheffield played an integral role in acquiring William Osler’s new rapid comprehensive next generation sequencing technology, making Osler the first community hospital in the world to offer this type of genetic testing in-house for their cancer patients.
Brandon also served as a steering committee member on IMPACT Medicom’s CGP prioritization report. The full report can be downloaded at: https://www.impactmedicom.com/publications/reports
This podcast episode was sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to IMPACT Medicom’s MYTHBUSTER series, addressing COVID-19 vaccine hesitancy. This series is aimed at health care professionals who are on the front lines of vaccine delivery, to help address common sources of misinformation around COVID-19 vaccines.
In the second episode of the series, hosted by Anna Christofides (owner of IMPACT Medicom), we discuss with Dr. Lynora Saxinger:
- Common concerns that may lead to COVID-19 vaccine hesitancy
- The scientific evidence behind these concerns and how they can be addressed with patients
- The latest safety data, in particular, the risk of blood clots
- Data around length of immunity and optimal dosing schedules
Our guestDr. Lynora Saxinger is a world-renowned infectious disease specialist, based at the University of Alberta. Dr. Saxinger has been at the forefront of the media, becoming a National public figure in the discussions around COVID-19.
This podcast episode is sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
Welcome to IMPACT Medicom’s MYTHBUSTER series, addressing COVID-19 vaccine hesitancy. This series is aimed at health care professionals who are on the front lines of vaccine delivery, to help address common sources of misinformation around COVID-19 vaccines.
In the second part of the first episode of the series, hosted by Anna Christofides (owner of IMPACT Medicom), we continue the discussion on:
- Addressing Vaccine Hesitancy: Common sources of misinformation around COVID-19 vaccination and how these can be addressed
- Improving Vaccine Access: The use of mass vaccination and popup clinics to provide better access to higher risk populations
Our guestDr. Kelly Grindrod is an associate professor at the University of Waterloo’s School of Pharmacy. She is the pharmacy lead for the Waterloo Region vaccine task force and helped set up a mass vaccine clinic at the University of Waterloo School of Pharmacy. Dr. Grindrod has also led the development of several online resources including the Pharmacy5in5.ca platform, which includes videos and infographics on COVID vaccines.
This podcast episode is sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
Episode is Live
Published: Apr. 14, 2021 @ 2PM Edit
Unpublish
Add a Transcript
Get episode better indexed by search engines.
Add Chapter Markers
Listeners can tap through & see what’s coming up.
Create a Visual Soundbite
Best way to share to social media for engagement.
Share Episode On
More Options
Email Link to Episode
Copy
Direct Link to MP3
Copy Download MP3
Embed this ONE Episode
Welcome to IMPACT Medicom’s MYTHBUSTER series, addressing COVID-19 vaccine hesitancy. This series is aimed at health care professionals who are on the front lines of vaccine delivery, to help address common sources of misinformation around COVID-19 vaccines.
In our first episode of the series, hosted by Anna Christofides (owner of IMPACT Medicom), we discuss with Dr. Kelly Grindrod:
- Addressing Vaccine Hesitancy: Common sources of misinformation around COVID-19 vaccination and how these can be addressed
- Improving Vaccine Access: The use of mass vaccination and popup clinics to provide better access to higher risk populations
Our guestDr. Kelly Grindrod is an associate professor at the University of Waterloo’s School of Pharmacy. She is the pharmacy lead for the Waterloo Region vaccine task force and helped set up a mass vaccine clinic at the University of Waterloo School of Pharmacy. Dr. Grindrod has also led the development of several online resources including the Pharmacy5in5.ca platform, which includes videos and infographics on COVID vaccines.
This podcast episode is sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:
· The BC OncoPanel, a comprehensive genomic profiling (CGP) test available to patients with some cancers in British Columbia;
· The challenges for including CGP in laboratory budgets;
· The information exchange needed between stakeholders to accelerate access to CGP; and
· How IMPACT Medicom’s CGP prioritization report can provide decision-makers with a framework for implementing CGP testing.
Our guests:Dr. Howard Lim is a Medical Oncologist at BC Cancer Agency and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia. He completed his medical oncology training at the BC Cancer Agency and received additional training at the Oregon Health Sciences University, specializing in gastrointestinal malignancies. Dr. Lim is actively involved in clinical trials, ethics, and genomic-based research.
Jim Slater [MLT(ART), BSc, MBA] began his career as a medical laboratory technician in BC and has since worked in all four Western provinces in the area of diagnostic services. His past leadership roles include Executive Director of all diagnostics in Saskatchewan, Chief Executive Officer of all diagnostic services in Manitoba, and most recently, Chief Provincial Diagnostics Officer at the Provincial Health Services Authority in BC. Jim currently provides Health System and Business Consulting services, with expertise in precision medicine (genomics), value-based healthcare, innovation and resource stewardship, research, and business development.
Howard and Jim both served as steering committee members on IMPACT Medicom’s CGP prioritization report. The full report can be downloaded at:
https://www.impactmedicom.com/publications/reports.
This podcast episode is sponsored by AstraZeneca Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
Welcome to our podcast series on precision medicine in oncology. In this first episode of the series, we discuss the importance of comprehensive genomic profiling (CGP) as a critical tool for treating patients with advanced solid tumors.
Included is a discussion of:
- The CGP report, which is designed to aid Canadian decision makers in the prioritization of funding access to CGP testing in patients with solid tumors.
- The full report can be downloaded at:
https://www.impactmedicom.com/publications/reports.
Our guest:Dr. Sandeep Sehdev is a Medical Oncologist and Clinical Investigator at the Ottawa Hospital Cancer Centre. Dr. Sehdev served as a steering committee member in the development of the CGP report and is passionate about medical education, the application of technology in oncology, and patient advocacy.
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
In this episode, we discuss the use of Bruton’s Tyrosine Kinase (BTK) inhibitors for the treatment of patients with chronic lymphocytic leukemia (CLL).
Included is a discussion of:
- Novel treatments for CLL
- The impact of BTK inhibitors for the treatment of CLL
- The differences between first- (e.g. ibrutinib) and second-generation (e.g. acalabrutinib, zanubrutinib, tirabrutinib) BTK inhibitors
- Preliminary results from the ELEVATE-RR trial comparing the efficacy and safety of acalabrutinib vs ibrutinib in high-risk relapsed/refractory CLL (see: https://www.cancernetwork.com/view/acalabrutinib-meets-primary-end-point-versus-ibrutinib-in-previously-treated-high-risk-cll for the full press release)
Our guest:Dr. Carolyn Owen is an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. She completed her internal medicine training in Ottawa, followed by Hematology training in Vancouver and a research fellowship in molecular genetics at Barts and the London School of Medicine. Her current clinical interests are in the areas of low-grade lymphoma and chronic lymphocytic leukemia (or CLL) and she is the local principal investigator at the Tom Baker Cancer Centre for a number of clinical trials focusing on these areas.
Funding for this episode provided by AstraZeneca, Canada. If you in enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.
In this episode we discuss the management of CLL patients during the COVID-19 pandemic.
Included is a discussion of:
- The initial treatment of patients with CLL during COVID-19
- The use of BTK inhibitors vs FCR
- The use of intravenous or subcutaneous immunoglobulin
- Existing guidelines for the treatment of CLL during COVID-19
- The virtual management of CLL patients
**Our guest:
Dr. Pavic** is a Medical Oncologist and Chief of the Hemato-Oncology department at the Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre Hospitalier Universitaire de Sherbrooke and an assistant professor in the Faculty of Medicine and Health Sciences at the Université de Sherbrooke.
Guidelines
- ASH recommendations: https://www.hematology.org/covid-19/covid-19-and-cll
- Canadian recommendations: Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic: L.H. Sehn, P. Kuruvilla, A. Christofides, J. Stakiw https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339858/pdf/conc-27-e332.pdf
If you enjoy our podcast, please take the time to rate our podcast and subscribe****
For more great podcasts and other features, visit our website at: www.impactmedicom.com.
On today’s podcast episode, we discuss the virtual management of patients with inflammatory arthritis.
We are joined by:
- Dr. Janet Pope: Professor of Medicine in the Division of Rheumatology, Epidemiology and Biostatistics at the University of Western Ontario.
Our episode includes a discussion of:
- The use of a virtual platform for managing patients with inflammatory arthritis.
- Which patients should be seen in person rather than virtually.
- Barriers to virtual assessment, including measuring swollen and tender joints, co-morbidities, and overall health.
- Patient barriers to virtual care such as familiarity with technology, language barriers, memory issues, etc...
- Whether there are disease-related risk factors for patients with inflammatory arthritis.
- Treatment modifications such as whether we should "treat-to-target" and if modifications are needed during the COVID-19 pandemic.
If you enjoy our podcast, please take the time to rate our podcast and subscribe****
For more great podcasts and other features, visit our website at: www.impactmedicom.com.
In this episode, we discuss the opioid epidemic in Canada and the use of naloxone, a life-saving drug that is used to prevent death from opioid overdose, with pharmacists: Dr. Ross Tsuyuki and Mark Barnes.
- Dr. Ross Tsuyuki - professor and chair of the Department of Pharmacology in the Faculty of Medicine and Dentistry at the University of Alberta.
- Mark Barnes - owner of Respect Rx Pharmaciesin Ottawa.
Our episode includes a discussion of:
- The extent of the opioid epidemic in Canada and how COVID-19 has impacted the number of opioid-related deaths.
- The use of the drug, naloxone, to prevent death from respiratory depression caused by opioid overdose. Naloxone is distributed as a nasal spray or injection kit and is supplied by pharmacists.
- The unique role of pharmacists in the distribution of naloxone for the fight against the opioid epidemic.
- Who should be given a naloxone kit and its relevance in general for anyone prescribed opioids.
- The development of the first published guidelines for Canadian pharmacists on prescribing naloxone. The guidelines can be found here: https://journals.sagepub.com/doi/pdf/10.1177/1715163520949973.
If you enjoy our podcast, please take the time to rate our podcast and subscribe****
For more great podcasts and other features, visit our website at: www.impactmedicom.com.
Dr. Ray Deonandan is a Canadian epidemiologist, assistant director, and associate professor at the University of Ottawa. In this episode, we discuss how we can exercise safely during the COVID-19 epidemic as the cold weather approaches.
- The importance of exercise for physical and mental health is discussed as well as tips for reducing the chance of COVID-19 transmission while exercising.
- We discuss the differences in transmission risk for adults vs children and the types of exercises that are safest for each age group.
- Topics such as whether we should wear a mask outside while exercising, whether sweat droplets increase transmission, and the length of exposure needed for transmission outside are discussed.
If you enjoy our podcast, please take the time to rate our podcast and subscribe****
For more great podcasts and other features, visit our website at: www.impactmedicom.com.